Hidroxizina Farmoz (Hydroxyzine Hydrochloride)

Hidroxizina Farmoz is prescribed for several clinical situations where its antihistamine and central nervous system effects are beneficial.

• Relief of itching and skin irritation associated with allergic reactions, such as urticaria or contact dermatitis.
• Management of anxiety, tension, or mild to moderate emotional stress.
• Pre‑operative or post‑procedural sedation to reduce patient anxiety and promote calmness.
• Prevention of nausea and vomiting related to surgery, anesthesia, or motion sickness.
• Adjunctive treatment of pruritus in chronic liver disease or renal failure (off‑label in some regions).

• Hydroxyzine hydrochloride acts primarily as a selective antagonist of peripheral H1 histamine receptors, preventing histamine‑mediated vasodilation, increased vascular permeability, and sensory nerve activation that cause itching and allergic symptoms. In addition, the compound crosses the blood‑brain barrier and exerts central anticholinergic and sedative effects by inhibiting histaminergic neurotransmission, which contributes to its anxiolytic and sleep‑inducing properties. It also displays weak antagonism at muscarinic receptors, which may augment its sedative profile.

Adverse reactions to Hidroxizina Farmoz are generally dose‑related and may vary in frequency.

Common

• Drowsiness or sedation, which may affect the ability to drive or operate machinery, especially after the initial dose.
• Dry mouth, throat, or nasal passages, often accompanied by a mild taste alteration.
• Dizziness or light‑headedness, sometimes related to postural changes.
• Blurred vision or difficulty focusing, usually transient.

Serious

• Severe allergic reaction (anaphylaxis) presenting with widespread rash, facial swelling, or respiratory distress.
• Cardiac arrhythmias, including QT interval prolongation that can lead to palpitations or fainting.
• Marked hypotension or syncope, particularly when combined with other sedatives.
• Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia, which are uncommon but may require medical attention.

Before initiating Hidroxizina Farmoz, healthcare providers should evaluate several patient‑specific factors to minimize risk.

• Assess for hypersensitivity to hydroxyzine or other antihistamines.
• Use caution in hepatic or renal impairment because clearance may be reduced.
• Evaluate cardiac history, especially arrhythmias or prolonged QT interval.
• Avoid combining with CNS depressants such as alcohol, benzodiazepines, or opioids.
• Consider pregnancy and lactation; use only if benefit outweighs risk.
• Monitor elderly for excessive sedation, falls, or anticholinergic effects.

Hydroxyzine may interact with several medicines, altering its sedative effect or cardiac safety.

Avoid

• Concomitant use with other potent CNS depressants (e.g., barbiturates, high‑dose benzodiazepines, or general anesthetics) due to additive sedation and respiratory depression.
• Co‑administration with drugs that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, or antipsychotics) because of increased risk of cardiac arrhythmias.

Use with caution

• Alcohol, because it can enhance drowsiness and impair coordination.
• Anticholinergic agents (e.g., diphenhydramine, atropine) which may increase anticholinergic burden and dry‑mouth effects.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that could significantly raise hydroxyzine plasma concentrations.